BioNTech nabs up to $90M for mpox vaccine as it begins PhI/II trial behind Moderna's lead
Building on its infectious disease work in Covid-19, malaria and tuberculosis, BioNTech is now rolling out a Phase I/II test of a jab to protect against the mpox virus, which caused international concern in the summer of 2022 but has since waned.
Like its Covid-19 vaccine counterpart Moderna, the German biotech is hoping to create an mRNA-based vaccine for mpox, which can lead to irritable skin lesions, rashes and painful swelling of the lymph nodes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.